Systemic Drug Delivery Strategies. Volume 2 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy


Book
August 2021
Elsevier Science and Technology
ID: 5308649

Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 examines the challenges of delivering immuno-oncology therapies, focusing specifically on the multiple technologies of affective drug delivery strategies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses methods of targeting tumors, CRISPR technology, and vaccine delivery among many other delivery strategies.

Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

1. Delivery strategies for immune checkpoint blockade inhibitors
2. Delivery strategies for ex vivo and in vivo T-cell reprogramming
3. Delivery strategies for ex vivo and in vivo NK cell reprogramming
4. Delivery strategies for tumor-associated macrophage reprogramming
5. Reprogramming lymphocytes for tumor immunotherapy
6. Targeting tumor-associated neutrophils in immunotherapy
7. Targeting tumor-associated fibroblast in immunotherapy
8. Oncolytic viral particle delivery
9. Extracellular vesicles (exosomes) in tumor immunotherapy
10. Nucleic acid-based delivery and reprogramming for tumor immuno-oncology
11. CRISPR-based gene editing in cancer immunotherapy
12. Delivery strategies for glioma immunotherapy
13. Delivery strategies for STING agonists
14. Delivery strategies for cancer vaccine and immunoadjuvant
15. Targeted delivery and reprogramming myeloid-derived suppressor cells (MDSC) in cancer
16. Delivery of radio-immunotherapy for solid tumors
17. Delivery of photo-immunotherapy for cancer
18. Local immunotherapy of cancer and metastasis
19. Delivery strategies to overcome tumor immunotherapy resistance

Authors

Mansoor M. Amiji Distinguished Professor and Chairman, Department of Pharmaceutical Sciences, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts, USA. Mansoor M. Amiji is the Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences at the Bouv� College of Health Sciences at Northeastern University. Dr. Amiji has edited a number of books and is a frequently published author. His research focuses on the synthesis of novel polymeric materials for medical and pharmaceutical applications, drug delivery systems and nanomedical technologies, and his contributions in research advising, grant reviews for various organizations and editorial work for journals are invaluable. Lara Scheherazade Milane Assistant Teaching Professor in Biotechnology, Bouve College of Health Sciences, Northeastern University, USA. Dr. Lara Milane is Assistant Teaching Professor in Biotechnology at the Bouv� College of Health Sciences at Northeastern University. She is interested in Mitochondrial Medicine. She is working on developing nanomedicines for a range of diseases (cancer, neurodegenerative disease, aging) that manipulate mitochondria for therapeutic outcomes. Dr. Milane was trained as a National Cancer Institute/ National Science Foundation Nanomedicine Fellow at Northeastern University, Boston, MA. Dr. Milane is an intuitive cancer biologist with research interests in developing translational nanomedicines that exploit the hallmarks of cancer.

Table of Contents

Authors

Related Topics

Related Products

Viral Vectors in Cancer Immunotherapy. International Review of Cell and Molecular Biology Volume 379

Immuno-Oncology - Global Strategic Business Report

Cancer Immunotherapy Market 2025-2029 - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant Guides

Cancer Immunotherapy Market Report 2025

Immunotherapy Drugs - Global Strategic Business Report